The Bosch Institute for Clinical Pharmacology will deliver pharmacogenomic recommendations to physicians and let patients see their test results on the web.
Newly launched aggregator Seqster will help Boston University researchers collect data from EHRs, wearables, and gene tests to identify concussion biomarkers.
Precision cancer company Syapse is teaming with Seoul National University Hospital and Asian AWS partner Megazone
Three-month-old health data integrator Datavant hopes its analytics technology can improve the speed and success of clinical trials.
The company, which first signed on to provide services to the VA's Million Veteran Program in 2013, will provide the department with 34,000 more genomes.
The firm plans to develop and evaluate the utility of an ethnically diverse group of metastatic prostate cancer patient-derived xenograft models.
Scotland's Arrayjet will provide the Bronx-based NYBC with microarray instrumentation, printing, and expertise under an approximately $250,000 contract.
The company will work with researchers from the University of North Texas Health Science Center to develop better software for forensics.
Stat News examines ethical questions raised by Alphabet's Verily awarding a research contract to a clinic mostly owned by its CEO.
Genomics England has selected WuXi Nextcode to interpret genomic data from cancer and rare disease samples as part of the UK 100K Genomes Project.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.